Subcategory Detail
Interagency Autism Coordinating Committee (IACC) logo
Office of Autism Research Coordination (OARC) logo

Medical/Pharmacologic$10,960,296.00
Fiscal Year: 2010
  

Download 2010 Medical/Pharmacologic projects (EXCEL)
This subcategory includes research on drugs (e.g., antidepressants, anticonvulsants, antipsychotics, anxiolytics, melatonin, and stimulants) to treat autism and its co-occurring conditions, as well as medical therapies such as transcranial magnetic stimulation (TMS).
Graph: The subcategories for Question 4 illustrate the many approaches to treatments and interventions supported by autism research funders. The largest amount of funding supported projects to develop Model systems and therapeutic targets (35%), followed by research on Behavioral interventions (29%). Medical/Pharmacologic interventions received 16% of funding, classroom-based interventions (Educational) received 10% of funding, and Technology-based interventions and supports received 7% of funding. The subcategories with the smallest amounts of funding included Occupational, physical, and sensory-based (2%) and Complementary, dietary, and alternative (1%).
Note: Initial Sort is by Principal Investigator. Sorting by other columns is available by clicking on the desired column header.
Project Title Principal Investigator Strategic Plan Objective Institution
Trial of a glutamate antagonist in the treatment of OCD and autistic disorders Swedo, Susan Q4.L.A National Institutes of Health
Treatment of sleep problems in children with autism spectrum disorder with melatonin: A double-blind, placebo-controlled study Hopkins, Bobbi Q4.S.A Baylor College of Medicine
Treatment of sleep problems in children with autism spectrum disorder with melatonin: A double-blind, placebo-controlled study Hopkins, Bobbi Q4.S.A Baylor College of Medicine
The effects of oxytocin on complex social cognition in autism spectrum disorders Bartz, Jennifer Q4.L.A Mount Sinai School of Medicine
Targeted pharmacologic interventions for autism McDougle, Christopher Q4.L.C Indiana University-Purdue University Indianapolis
Survey on treatment for children with autism with and without seizures Frye, Richard Q4.Other Children's Learning Institute
Randomized phase 2 trial of RAD001 (an MTOR inhibitor) in patients with tuberous sclerosis complex Sahin, Mustafa Q4.L.A Childrens Hospital Boston
Predictors of effects of propranolol on language & connectivity in autism Beversdorf, David Q4.S.F University of Missouri
Pharmacotherapy of pervasive developmental disorders Stigler, Kimberly Q4.L.C Indiana University-Purdue University Indianapolis
Neuronal nicotinic receptor modulation in the treatment of autism: A pilot trial of mecamylamine Arnold, L. Eugene Q4.L.A The Ohio State University
Mirtazapine treatment of anxiety in children and adolescents with pervasive developmental disorders McDougle, Christopher Q4.L.C Indiana University
Intranasal oxytocin for the treatment of children and adolescents with autism spectrum disorders (ASD) Anagnostou, Evdokia Q4.S.C Holland Bloorview Kids Rehabilitation Hospital
Developing treatment, treatment validation, and treatment scope in the setting of an autism clinical trial Johnson, William Q4.L.A University of Medicine & Dentistry of New Jersey - Robert Wood Johnson Medical School
Developing treatment, treatment validation, and treatment scope in the setting of an autism clinical trial Stein, Peter Q4.L.A University of Medicine & Dentistry of New Jersey
Developing treatment, treatment validation, and treatment scope in the setting of an autism clinical trial Novotny, Sherie Q4.L.A University of Medicine & Dentistry of New Jersey - Robert Wood Johnson Medical School
Clinical Trials Network Staff Member Q4.L.A Autism Speaks (AS)
Building a selective inhibitory control tone in autism: An rTMS study Casanova, Manuel Q4.Other University of Louisville
Biomarkers in Autism of Aripiprazole and Risperidone Treatment (BAART) Devane, C. Lindsay Q4.S.F Medical University of South Carolina
Autism Intervention Research Network on Physical Health (AIR-P network) Perrin, James Q4.S.A Massachusetts General Hospital
Association of cholinergic system dysfunction with autistic behavior in fragile X syndrome: Pharmacologic and imaging probes Reiss, Allan Q4.L.A Stanford University
ACE Network: Early pharmacotherapy guided by biomarkers in autism Chugani, Diane Q4.S.F Wayne State University
ACE Center: Understanding repetitive behavior in autism McCracken, James Q4.L.A University of California, Los Angeles
ACE Center: The pharmacogenetics of treatment for insistence sameness in autism Owley, Thomas Q4.L.A University of Illinois at Chicago
4/4-RUPP Autism Network: Guanfacine for the treatment of hyperactivity in PDD Scahill, Lawrence Q4.L.C Yale University
3/4-RUPP autism network: Guanfacine for the treatment of hyperactivity in PDD McCracken, James Q4.L.C University of California, Los Angeles